Shield Therapeutics (LON:STX) Stock Price Down 15.1% – Time to Sell?

Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price was down 15.1% during mid-day trading on Tuesday . The stock traded as low as GBX 4.83 and last traded at GBX 5.16. 6,491,320 shares traded hands during trading, an increase of 171% from the average daily volume of 2,396,552 shares. The stock had previously closed at GBX 6.08.

Shield Therapeutics Price Performance

The stock’s 50-day moving average price is GBX 5.29 and its 200 day moving average price is GBX 6.84. The firm has a market cap of £53.50 million, a price-to-earnings ratio of -5.00 and a beta of 1.77. The company has a quick ratio of 2.16, a current ratio of 0.75 and a debt-to-equity ratio of -146.28.

Shield Therapeutics Company Profile

(Get Free Report)

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.

Further Reading

• Five stocks we like better than Shield Therapeutics
• This Corner of the Market Is Outperforming the Benchmark—And It’s Not AI
• Victoria’s Secret’s Comeback Is Real—The Stock’s Problem Is Different
• Apple Unveils Foldable iPhone, But Stock’s Muted Reaction Raises Questions
• Palantir’s New U.S. Army Contract Brings It Closer to Owning the Full Battlefield System